Symptom scores and clinical measures in benign prostatic hyperplasia

Table 7 Narrative synthesis: Key clinical findings and practice implications derived from primary studies included in the meta-analysis¹

Ref.	Country	Key clinical findings	Practice implications
Kohler and Kausik[16], 2023	United States	IPSS has statistically significant but weak correlations with Qmax, voided volume, and PVR in an unselected population (n = 1014); subjective symptom severity does not reliably predict objective voiding parameters	Holistic assessment mandate: Clinical and reimbursement pathways must integrate subjective symptom scores with objective voiding profiles; surgical decision-making must not be based on symptom scores alone
Mbouché et al[1], 2022	Cameroon	IPP correlates more strongly with low Qmax and AUR risk than with overall prostate volume; IPP grade > 10 mm confers significantly elevated obstruction risk, even with modest total PV	Diagnostic standardization: Ultrasound protocols for LUTS/BPH should mandate systematic IPP measurement and grading alongside PV and PVR; IPP is non-invasive, adds no equipment cost, and improves prognostic accuracy
Taneja et al[7], 2017; Timilsina et al[23], 2024	India/Nepal	High illiteracy rates render the IPSS difficult to complete without clinician assistance; the pictogram-based VPSS correlates strongly with IPSS and uroflowmetry parameters and takes less time to complete unaided	Tool adaptation: VPSS should be adopted as a first-line or co-administered assessment tool in developing nations and low-literacy populations to eliminate interviewer bias and improve the accuracy of symptom scoring
Anyimba et al[3], 2023	Nigeria	Interviewer-assisted IPSS administration introduces systematic reporting bias, attenuating the observed correlation between reported symptoms and objective Qmax/PVR in low-literacy settings	Minimizing measurement bias: Healthcare policies in low-resource settings must account for interviewer-assisted questionnaire subjectivity; objective ultrasonographic imaging and VPSS adoption should be prioritized as complementary tools
Awaisu et al[9], 2021	Nigeria	Patients present late because LUTS are falsely attributed to normal ageing; PV correlates significantly with IPSS at presentation (r = 0.179), reflecting delayed healthcare-seeking and low BPH community literacy	Public health and early triage: Community education campaigns are needed to decouple LUTS from “normal agein” where uroflowmetry is unavailable, PV combined with IPSS serves as a practical triage tool for urgency of referral
Fazal et al[12], 2025	Pakistan	Strong IPSS-PVR correlation (r = 0.920) in a tertiary referral population with advanced disease; UTIs are highly prevalent in older BPH patients with severe LUTS and elevated residual urine volumes	Comorbidity management: BPH protocols must incorporate routine urine culture and sensitivity testing for all patients with PVR ≥ 100 mL, even without overt infective symptoms; microbiological surveillance alongside ultrasonography is clinically imperative
Ngwa-Ebogo et al[24], 2023	Cameroon	Weak-to-moderate PV-IPSS correlation (r = 0.410); confirms that prostate size is a poor standalone predictor of symptom bother; large volume does not reliably indicate severe or treatment-requiring LUTS	Surgical criteria refinement: PV alone is insufficient for clinical or surgical decision-making; guidelines should require composite assessment - incorporating symptom score, uroflowmetry, PVR, and IPP grade - rather than volume thresholds in isolation
Shah et al[11], 2024	Pakistan	Strong correlations between IPSS and both PV (r = 0.779) and PVR (r = 0.599) in a tertiary urology population with advanced disease burden at presentation	Tertiary care pathway: The strength of IPSS correlations in tertiary settings reflects advanced-stage disease, not baseline population parameters; policies should prioritize earlier primary care intervention to reduce disproportionate burden on tertiary facilities

¹Practice implications derived from primary study findings within the context of current European Association of Urology/American Urological Association guidelines. All studies were cross-sectional unless otherwise stated. AUR: Acute Urinary Retention; BPH: Benign prostatic hyperplasia; IPP: Intravesical prostatic protrusion; IPSS: International Prostate Symptom Score; PV: Prostate volume; PVR: Post-void residual; Qmax: Maximum urinary flow rate; QoL: Quality of life; UTI: Urinary tract infection; VPSS: Visual Prostate Symptom Score; LUTS: Lower urinary tract symptoms.